Literature DB >> 3917275

Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus.

Y Murakawa, S Takada, Y Ueda, N Suzuki, T Hoshino, T Sakane.   

Abstract

Normal immunoregulation depends on a complex set of cellular interactions in which interleukin 2 (IL 2) appears to play an important role. We have examined the IL 2 activity in patients with systemic lupus erythematosus (SLE). IL 2 production by phytohemagglutinin (PHA)-stimulated T cells for 48 hr was measured by the ability of their culture fluid to induce proliferation of normal human T cells that had been activated for more than 20 days by PHA plus IL 2. To measure IL 2 responsiveness, T cells were blasted by preincubation with concanavalin A for 96 hr and stimulated for another 72 hr with lectin-free standard IL 2. SLE T cells failed to produce normal levels of IL 2 in vitro compared with normal control T cells. This failure resided in both OKT4+ and OKT8+ cells. Furthermore, the abnormality was due neither to soluble inhibitory factors produced by SLE T cells nor to active suppressor cells that might be induced by PHA-stimulation. Responsiveness to IL 2 of T cells from some, but not all, SLE patients was decreased significantly from that of normal controls. Absorption studies as well as studies with anti-Tac antibody demonstrated that the impaired responsiveness of T cells in the specific patients with SLE was due to inadequate expression of IL 2 receptors on the T cells upon activation. This defect was exclusively ascribed to the dysfunction of OKT4+, but not OKT8+, cells. The above defects in production of and responsiveness to IL 2 observed in patients with SLE were present at all times regardless of the disease activity or of corticosteroid therapy. Thus, the deficient IL 2 activity may be intrinsic to SLE lymphocytes and may contribute to impaired immunoregulation and to the development of SLE.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917275

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings.

Authors:  M Gelati; E Lamperti; A Dufour; E Corsini; E Venegoni; C Milanese; A Nespolo; A Salmaggi
Journal:  Ital J Neurol Sci       Date:  1997-08

2.  Normal mitogen-induced suppression of the interleukin-6 (IL-6) response and its deficiency in systemic lupus erythematosus.

Authors:  R J Warrington; W J Rutherford
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317

3.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

4.  Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens.

Authors:  J Martorell; J Font; I Rojo; R Vilella; M Ingelmo; J Vives
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

5.  Interleukin-2 production in Brown-Norway rats with HgCl2-induced autoimmune disease: paradoxical in vivo versus in vitro findings.

Authors:  D Baran; O Lantz; P Dosquet; A Sfaksi; P Druet
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

6.  Spontaneous recovery of the decreased expression in vitro of interleukin 2 receptors in rheumatoid arthritis.

Authors:  C Plater-Zyberk; K A Rockett; R N Maini
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

7.  Modulation of the IL-2 production defect in vitro in Graves' disease.

Authors:  Z Eisenstein; E Engelsman; M Weiss; Y Kalechman; B Sredni
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  Dehydroepiandrosterone in systemic lupus erythematosus.

Authors:  Amr H Sawalha; Susan Kovats
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

9.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

10.  Impaired T-cell activation in patients with systemic lupus erythematosus.

Authors:  S Sierakowski; E J Kucharz; R W Lightfoot; J S Goodwin
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.